3 Actions to Restore 2019 Purchasing Power—Through the Bioeconomy

November 19, 2026 |

Affordability, affordability, affordability. We hear it everywhere, all at once.

People don’t want another lecture about inflation. They don’t want to hear that prices are rising more slowly, as though a grocery bill that climbed 35 percent has somehow become affordable because it’s only climbing another two percent this year. They want their 2019 purchasing power back—at the gas pump, the grocery checkout, and the pharmacy counter.

Can it be done? We think so. And the bioeconomy can be at the heart of it. No grand new bureaucracies. No trillion-dollar transformation plans.  Just a fresh deal of the cards.

1. Energy: The Ten Percent Lane

There’s a peculiar feature of the global petroleum economy. Demand is relatively inelastic in the short run, which means that relatively small differences between supply and demand can produce surprisingly large changes in price. When petroleum supplies tighten, motorists cannot simply stop driving to work, farmers cannot park their tractors, and freight companies cannot announce that groceries will be delivered next Thursday when diesel prices become more agreeable. Consumers pay, because they have little choice.

But what if we could remove a meaningful sliver of demand from petroleum markets by supplying some of those same fuel needs from somewhere else? What if that reduced demand were enough to ease pressure on petroleum prices, potentially lowering the cost of the remaining petroleum gallons as well as the renewable gallons that displaced them?

Here’s the Fresh Deal: Make good on the renewable-fuels commitments governments have already made, and establish a dependable ten percent lane for competing fuels wherever those commitments provide the opportunity. Not another global mandate, not an attempt to drag countries already exceeding ten percent backward, and not a demand to dismantle the petroleum industry. Across the world, governments have already adopted renewable-fuels standards, blending requirements, and national targets. Some countries have surpassed ten percent; others have fallen short of their ambitions or struggled to turn policy into actual gallons.

The opportunity is to finish what we’ve already started.

The United States has largely completed its transition to E10. Brazil has demonstrated how much further blending can go. Commercial ethanol, biodiesel, and renewable diesel industries exist today, with established technologies and substantial production experience. What they need internationally is predictable market access that allows competing suppliers to invest, expand, trade, and improve their economics.

And here’s why ten percent matters.

Petroleum is not simply a fuel. It’s an industrial civilization, supported by refineries, pipelines, terminals, trading networks, vehicle fleets, financing arrangements, and a century of accumulated investment. Much of that infrastructure was paid for long ago. A renewable molecule may be cheaper or better suited to a particular use, yet still find itself facing the enormous cost of entering a system built around something else.

Petroleum already has the highways, the tollbooths, and the filling stations. A biofuel shouldn’t have to finance an entirely new highway system before selling its first gallon. The ten percent lane doesn’t bulldoze the other ninety percent. It gives alternatives a dependable space to compete, establish their own supply chains, attract financing, and improve their performance.

Think of the mammals living in the age of dinosaurs. The dinosaurs don’t need to be defeated for the mammals to succeed. They need sufficient habitat to develop, diversify, and establish themselves. Eventually the world changes, and the value of having preserved more than one evolutionary pathway becomes obvious. The same principle applies to industrial systems. A superior substitute can fail commercially because the systemwide cost of adopting it overwhelms its individual advantage. Providing a bounded, functioning market for alternatives is one way to prevent that outcome. And unlike the dinosaurs, petroleum producers can participate in the new ecosystem. Many already do.

Now, renewable fuels aren’t automatically cheaper. Feedstock prices matter, different fuels have different energy content, and petroleum producers may adjust their output. Expanding renewable-fuel demand can also raise agricultural costs. That’s why our objective cannot simply be gallons blended or compliance certificates generated. We must measure whether the complete arrangement reduces net consumer fuel costs, including its effects on food prices.

But the upside is compelling. A larger international market for renewable fuels can diversify supply, increase competition, and potentially relieve pressure in a petroleum market where small imbalances can have large consequences.

And diesel savings don’t stop at the pump. Diesel moves the groceries, harvests the crops, and powers much of the industrial economy. Lower transportation costs can help lower costs elsewhere in the household budget.

2. Food: The Nineteen-Cent Reality Check

Here’s one of the most remarkable numbers in American agriculture. For every dollar consumers spend on domestically produced food, the farmer receives roughly nineteen cents.

Where do the other eighty-one cents go?

Processing, packaging, refrigeration, transportation, warehousing, distribution, retail operations, advertising, and everything else between the furrow and the front register. Much of that is necessary and valuable. Food must be processed safely, kept fresh, transported reliably, and delivered conveniently. But that doesn’t mean the system has discovered the least expensive way to accomplish those tasks.

Consider the supermarket aisle. Two packages of rolled oats sit side by side. One has an advertising budget, a carefully cultivated brand personality, an elaborate carton, and perhaps a celebrity somewhere assuring us that these oats possess a spiritual depth unavailable to ordinary breakfast cereals. The other package contains oats. Millions of consumers would happily take the second package if it delivered the same quality for substantially less money. Private-label brands have already demonstrated that shoppers will trade marketing expense for grocery savings when quality and availability are comparable. Now imagine applying that principle systematically to a basket of everyday staples—milk, eggs, flour, grains, cooking oils, and the essentials that turn a weekly shopping trip into a household financial event.

We already have an institution designed to support agricultural markets and the movement of American abundance: the USDA’s Commodity Credit Corporation, created in the 1930s and still operating today. Why not put it to work on affordability at the supermarket?

The Fresh Deal proposes a $2 billion competitive infrastructure challenge for affordable staple foods, built around the CCC’s existing agricultural-market mission.

Invite private manufacturers, cooperatives, processors, distributors, and grocery chains to propose efficient regional processing hubs, shared packaging facilities, standardized staple-food lines, and distribution arrangements designed to cut avoidable costs. Use existing CCC powers where they fit and obtain any additional authority required for particular investments.

We’re not proposing a government cereal brand, federal grocery stores, or a five-year commission to determine the appropriate size of an oatmeal box. We’re proposing a competition to see who can deliver essential foods to consumers at the lowest sustainable cost, with quality and safety preserved.

There would be one nonnegotiable condition: No verified savings, no continuing support. The objective is to restore 2019 purchasing power for a core basket of staples, and to challenge participants to achieve actual 2019 price points wherever the economics permit. If one approach works, replicate it. If another fails, stop financing it. If an unexpected processing or distribution technology offers greater savings, let it compete for the business. The principle is neither radical nor particularly complicated. Public support purchases a measurable public benefit, not merely a building, a ribbon-cutting ceremony, or another annual report full of admirable intentions.

American farmers have spent generations driving enormous gains in agricultural productivity. Yet those improvements do not automatically translate into cheaper grocery baskets when most of the retail food dollar is spent after the commodity leaves the farm.

3. Pharmaceuticals: Speed in Exchange for Price

The third great household affordability challenge sits behind the pharmacy counter, where the relationship between what a medicine costs to develop, what it costs to manufacture, what insurers and intermediaries negotiate, and what the patient ultimately pays can resemble a detective novel whose final chapter has gone missing.

Fortunately, biotechnology has already shown us something extraordinary about the economics of pharmaceutical development. Operation Warp Speed.

During the COVID-19 emergency, industry, government, researchers, and regulators demonstrated that the conventional pharmaceutical development calendar was not necessarily the fastest achievable calendar. Clinical activities could overlap where scientifically justified, regulatory engagement could happen earlier, and manufacturing capacity could be developed before final authorization rather than waiting for each preceding stage to finish. None of this eliminated the need for rigorous scientific evaluation. Nor could the extraordinary circumstances of the pandemic be reproduced for every therapy. But the effort demonstrated that better coordination can save substantial time.

And time is money. Every avoidable month of development consumes financing, personnel, laboratory capacity, manufacturing resources, and management attention. So, here’s the bargain: Speed in exchange for price.

Offer qualifying pharmaceutical developers an intensified affordability pathway using existing FDA consultation, coordination, and expedited mechanisms wherever medically and legally appropriate. In return for development efficiencies and reduced uncertainty, manufacturers would commit to measurable, enforceable reductions in what patients actually pay. Not a reduction in a theoretical list price that disappears somewhere between the manufacturer and the pharmacy. Not an impressive rebate that never reaches the patient. Real savings on the receipt.

A biosimilar is not the same as a novel cancer therapy. A mature treatment for a widespread chronic condition is not the same as an experimental medicine for a rare disease. The scientific requirements, commercial incentives, and potential savings will differ, and no affordability bargain should compromise the evidence needed to establish safety and effectiveness. But where development can be made more efficient, let’s ask who receives the economic benefit. If the FDA needs a wider lane from Congress to make a particular speed-for-price bargain enforceable, clear the traffic.

We have already demonstrated that remarkable development acceleration is sometimes possible when institutions cooperate. Now let’s make patient affordability an explicit part of the commercial proposition.

The Government That Knows How to Learn

There is one more ingredient in the Fresh Deal, and it may be the most important.

In biotechnology, we have an operating philosophy called Design–Build–Test–Learn. Develop an idea, build the process, measure what happens, learn from the results, and improve the next version. It’s how fermentation strains become more productive, factories become more efficient, and technologies move from laboratory curiosities to commercial products. Washington sometimes seems to operate on a different system: Argue–Build–Argue–Discard. In synthetic biology, if a strain fails in the fermenter, you investigate the failure, modify the design, and run the next batch. Washington has a remarkable habit of building monuments to first drafts.

Let’s try something different.

The Fresh Deal is not a collection of permanent entitlements or a promise that three policy designs conceived today will remain optimal in 2040. It is an invitation to use institutions already in place to test three practical ways of restoring household purchasing power. Make existing renewable-fuels commitments work, and measure net fuel savings. Test more efficient staple-food infrastructure, and measure what happens to grocery receipts. Exchange pharmaceutical development efficiencies for enforceable patient savings, and measure the results at the pharmacy counter.

There’s a deeper reason this matters.

Mature industrial systems become extraordinarily good at doing what they were originally designed to do. They accumulate specialized infrastructure, financing arrangements, relationships, standards, and dependencies. Those strengths can become weaknesses when something better comes along, because replacing one component may require changing an entire system.

The bioeconomy encounters this problem constantly. We develop superior processes and promising molecules, only to discover that the surrounding economy cannot—or will not—adopt them at a cost anybody can afford.

Our three remedies are deliberately limited. They create room for alternatives to compete without requiring wholesale reconstruction of the systems consumers already depend upon. They offer measurable savings today while preserving the capacity to evolve tomorrow.

For decades, the bioeconomy has asked consumers and governments to invest in avoiding a future catastrophe. That remains a worthy ambition. But a household struggling with today’s prices cannot live on promises about 2050, and the industry cannot build its entire commercial future around the return of a favorable political climate.

We are not asking families for another decade of patience, another argument over climate targets, or another assurance that biotechnology will eventually trickle down. We’re asking the bioeconomy to deliver now. Fuel. Food. Medicine. Three urgent problems, three practical remedies, existing capabilities, and a government willing to learn. It’s time for a Fresh Deal—this time, let’s put the savings on the receipt.

Category: Top Stories

Thank you for visting the Digest.

}